APYX MEDICAL CORP
APYXNASDAQTrading Snapshot
- Day Range
- $619.55 – $630.68
- 52-Week Range
- $1.89 – $5.08
- Volume
- $2.82B
- Avg Volume
- $3.18B
- Shares Outstanding
- 41.9M
- Next Earnings
- Nov 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $53M
- Last Q Revenue
- $14M
- P/E Ratio
- —
- P/S Ratio
- 1.9x
- EPS (TTM)
- $-0.20
- Dividend Yield
- —
- Dilution (1yr)
- +10.3%
Why Investors Own APYX
- ✓High-growth profile — revenue up +9.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 74% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
APYX MEDICAL CORP
APYX
StockOtter · stockotter.spaceAbout APYX MEDICAL CORP
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
APYX MEDICAL CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift APYX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
APYX MEDICAL CORP announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.